The US Food and Drug Administration (FDA) has approved a new indication for the "
purple pill",
NEXIUM® (esomeprazole magnesium), for the treatment of Zollinger-Ellison Syndrome (ZES). Nexium is a prescription proton pump inhibitor marketed by
AstraZeneca (
AZN) for the treatment of
gastroesophageal reflux disease (GERD) in adults and children ages 12 to 17, and to reduce the risk of
NSAID-associated gastric ulcers in at-risk patients.
"Zollinger-Ellison Syndrome is the prototypical gastric acid hypersecretory condition. Patients with this condition require long-term antisecretory therapy to reduce their acid output to levels that are not injurious,” said David C. Metz, MD, Professor of Medicine, and Director of the Acid-Peptic Program, Division of Gastroenterology, University of Pennsylvania Health System. "NEXIUM provides early, effective, and sustained acid suppression to help in the management of this disease.”
Source:
AstraZeneca
.jpg)
Comment Preview